tiprankstipranks
Advertisement
Advertisement

BVNRY Stock Latest News

Bavarian Nordic’s Phase 3b Chikungunya Vaccine Trial Sets Up a New Catalyst for BVNRY Investors
Company AnnouncementsBavarian Nordic’s Phase 3b Chikungunya Vaccine Trial Sets Up a New Catalyst for BVNRY Investors
18d ago
BVNRY
Bavarian Nordic’s Earnings Call: Strong Growth Amid Challenges
PremiumCompany Announcements
Bavarian Nordic’s Earnings Call: Strong Growth Amid Challenges
4M ago
BVNRY
Bavarian Nordic Reports Strong Revenue Growth in 2025
PremiumCompany Announcements
Bavarian Nordic Reports Strong Revenue Growth in 2025
5M ago
BVNRY
New Phase 2b Trial by Icon Plc and Bavarian Nordic: A Closer Look at MVA-BN Vaccine Developments
PremiumCompany Announcements
New Phase 2b Trial by Icon Plc and Bavarian Nordic: A Closer Look at MVA-BN Vaccine Developments
5M ago
ICLR
Bavarian Nordic’s CHIKV VLP Vaccine Study: A Potential Game-Changer in Pediatric Immunization
PremiumCompany Announcements
Bavarian Nordic’s CHIKV VLP Vaccine Study: A Potential Game-Changer in Pediatric Immunization
5M ago
BVNRY
Bavarian Nordic’s MVA-BN Vaccine Study: A Potential Game-Changer in Orthopoxvirus Prevention
PremiumCompany AnnouncementsBavarian Nordic’s MVA-BN Vaccine Study: A Potential Game-Changer in Orthopoxvirus Prevention
5M ago
BVNRY
Officials confirm community spread of new Mpox strain in Southern CA, NBC says
Premium
The Fly
Officials confirm community spread of new Mpox strain in Southern CA, NBC says
5M ago
EBS
Bavarian Nordic Reports Strong Earnings and Growth
Premium
Company Announcements
Bavarian Nordic Reports Strong Earnings and Growth
7M ago
BVNRY
Bavarian Nordic Reports Strong H1 2025 Results
PremiumCompany Announcements
Bavarian Nordic Reports Strong H1 2025 Results
7M ago
BVNRY
Bavarian Nordic’s CHIKV VLP Vaccine Study: A Potential Game-Changer in Pediatric Chikungunya Prevention
PremiumCompany Announcements
Bavarian Nordic’s CHIKV VLP Vaccine Study: A Potential Game-Changer in Pediatric Chikungunya Prevention
8M ago
BVNRY
Bavarian Nordic’s Phase 2 Vaccine Trial Update: Key Insights for Investors
PremiumCompany Announcements
Bavarian Nordic’s Phase 2 Vaccine Trial Update: Key Insights for Investors
9M ago
BVNRY
Bavarian Nordic Reports Strong Q1 2025 Growth
PremiumCompany Announcements
Bavarian Nordic Reports Strong Q1 2025 Growth
11M ago
BVNRY
Bavarian Nordic’s Earnings Call: Strong Growth and Positive Outlook
PremiumCompany AnnouncementsBavarian Nordic’s Earnings Call: Strong Growth and Positive Outlook
11M ago
BVNRY
Bavarian Nordic A/S Reports Strong 2024 Earnings Amid Challenges
Premium
Company Announcements
Bavarian Nordic A/S Reports Strong 2024 Earnings Amid Challenges
1y ago
BVNRY
Bavarian Nordic Reports Strong 2024 Growth
Premium
Company Announcements
Bavarian Nordic Reports Strong 2024 Growth
1y ago
BVNRY
Bavarian Nordic Reports Strong Travel Health Growth in 2024
PremiumCompany Announcements
Bavarian Nordic Reports Strong Travel Health Growth in 2024
1y ago
BVNRY
Study suggests waning mpox protection from Jynneos vaccine, CIDRAP reports
PremiumThe Fly
Study suggests waning mpox protection from Jynneos vaccine, CIDRAP reports
2y ago
EBS
GOVX
Bavarian Nordic announces commercial availability of VAXCHORA in Canada
PremiumThe Fly
Bavarian Nordic announces commercial availability of VAXCHORA in Canada
2y ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
2y ago
EBS
MRVI
Applied Materials, H&R Block report quarterly beats: Morning Buzz
PremiumThe FlyApplied Materials, H&R Block report quarterly beats: Morning Buzz
2y ago
PL
FLO
Logistical issues with vaccine pose risk to mpox response, FT reports
Premium
The Fly
Logistical issues with vaccine pose risk to mpox response, FT reports
2y ago
EBS
Bavarian Nordic applies to EMA to use mpox vaccine in adolescents, FT reports
Premium
The Fly
Bavarian Nordic applies to EMA to use mpox vaccine in adolescents, FT reports
2y ago
EBS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >